FGFR2 C-terminal truncation in cancer

Human cancers frequently bear driver alterations in genes encoding receptor tyrosine kinases (RTKs), which has led to effective therapeutics targeting oncogenic signalling of RTK variants. Genomic alterations affecting fibroblast growth factor receptor 2 (FGFR2) occur in multiple cancer types, but clinical responses to FGFR inhibitors (FGFRi) have remained elusive, emphasising a need to better understand which FGFR2 alterations are oncogenic and targetable. Here we explored the FGFR2 status on human cancer cell lines.